DNB Asset Management AS Sells 3,958 Shares of Zoetis Inc. $ZTS

DNB Asset Management AS cut its holdings in Zoetis Inc. (NYSE:ZTS) by 3.4% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 111,327 shares of the company’s stock after selling 3,958 shares during the quarter. DNB Asset Management AS’s holdings in Zoetis were worth $17,361,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Nova Wealth Management Inc. bought a new position in shares of Zoetis during the first quarter valued at $25,000. 1248 Management LLC purchased a new position in Zoetis in the 1st quarter worth about $27,000. Saudi Central Bank bought a new position in Zoetis during the 1st quarter valued at about $29,000. REAP Financial Group LLC boosted its holdings in shares of Zoetis by 201.5% during the 2nd quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after acquiring an additional 131 shares during the last quarter. Finally, NewSquare Capital LLC boosted its holdings in shares of Zoetis by 69.1% during the 2nd quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock valued at $32,000 after acquiring an additional 85 shares during the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have recently weighed in on ZTS. Piper Sandler boosted their price objective on shares of Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Monday, August 11th. UBS Group decreased their target price on shares of Zoetis from $158.00 to $141.00 and set a “neutral” rating for the company in a research note on Wednesday, November 5th. Morgan Stanley dropped their price target on Zoetis from $211.00 to $175.00 and set an “overweight” rating on the stock in a research note on Monday, November 10th. BTIG Research cut their price objective on Zoetis from $200.00 to $160.00 and set a “buy” rating for the company in a report on Wednesday, November 12th. Finally, Argus reiterated a “buy” rating and set a $190.00 price objective on shares of Zoetis in a research report on Tuesday, September 9th. Six equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $178.89.

Zoetis Trading Up 5.3%

Shares of ZTS stock opened at $122.06 on Friday. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. The company has a market cap of $53.79 billion, a price-to-earnings ratio of 21.01, a PEG ratio of 2.31 and a beta of 0.90. Zoetis Inc. has a 1 year low of $115.25 and a 1 year high of $181.85. The firm has a fifty day moving average price of $137.75 and a 200-day moving average price of $150.17.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. The company had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.42 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.Zoetis’s revenue for the quarter was up .5% compared to the same quarter last year. During the same period last year, the firm earned $1.58 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be given a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.6%. The ex-dividend date of this dividend is Friday, October 31st. Zoetis’s payout ratio is presently 33.67%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.